Agios Pharmaceuticals (AGIO)
(Delayed Data from NSDQ)
$41.33 USD
+0.77 (1.89%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $41.31 -0.02 (-0.04%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Price, Consensus and EPS Surprise
AGIO 41.33 +0.77(1.89%)
Will AGIO be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for AGIO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for AGIO
Do Options Traders Know Something About Agios (AGIO) Stock We Don't?
FDA Grants Orphan Drug Tag to AGIO's Tebapivat for Rare Cancer
AGIO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why Is Zimmer (ZBH) Down 3.9% Since Last Earnings Report?
AGIO Q2 Earnings Lag, Stock Down on Missing Pediatric Study Goal
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Lags Revenue Estimates
Other News for AGIO
Agios cut at Leerink on overhang from Pfizer’s Oxbryta withdrawal
Agios Pharmaceuticals just downgraded at Leerink, here's why
Agios Pharmaceuticals price target raised to $57 from $52 at BofA
Notable Tuesday Option Activity: AGIO, AAOI, ACAD
Agios Announces FDA Orphan Drug Designation Granted to Tebapivat (AG-946) for Treatment of Myelodysplastic Syndromes (MDS)